Pioglitazone with sulfonylurea: glycemic and lipid effects in Taiwanese type 2 diabetic patients.
Tseng
Chin-Hsiao
CH
Division of Endocrinology and Metabolism, Department of Internal Medicine, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei, Taiwan. ccktsh@ms6.hinet.net
Huang
Tien-Shang
TS
D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D000077205:Pioglitazone; D013453:Sulfonylurea Compounds / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D013624:Taiwan; D045162:Thiazolidinediones / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D008055:Lipids; D013453:Sulfonylurea Compounds; D045162:Thiazolidinediones; D000077205:Pioglitazone